Iran Study Compares Costs of Three Weight Loss Drugs

A newly listed paper in the Journal of Diabetes and Metabolic Disorders reports a short term cost effectiveness analysis comparing three approved GLP-1 based medications, tirzepatide, semaglutide, and liraglutide, for obese and overweight patients who do not have diabetes, according to the PubMed listing.

This is an economic evaluation, not a clinical efficacy trial. That distinction matters because cost effectiveness research draws on existing trial data and local pricing or reimbursement models to estimate which treatment delivers the most value per dollar, rather than testing a drug head to head in patients. The detailed methodology and results are not available in the current listing, so we cannot report specific cost figures, quality adjusted life year estimates, or which medication the analysis favored.

All three compounds named here are approved medications in various markets for weight management or type 2 diabetes, with liraglutide and semaglutide carrying the longest regulatory track record and tirzepatide being the newest entrant. Studies like this one are common as health systems weigh how to allocate limited obesity treatment budgets, particularly in countries managing currency constraints and import costs for branded biologics. We will update this brief if the full text becomes accessible with usable data.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.